ClinicalTrials.gg
RecruitingNCT07655622DUAL-THRUSTUpdated Jun 18, 2026

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

A Phase 1/2 interventional study of Vebreltinib and Furmonertinib 80mg in Non-Small-Cell Lung Cancer, sponsored by Second Affiliated Hospital of Nanchang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Second Affiliated Hospital of Nanchang University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
25th of 41
45 · median 60
Started
2026
with 8 others
Phase 1/2
4 of 41
3 open now
Primary completion
2027-12
later than 22 of 33 live
Registered
41st of 41
by date

Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 25th largest by planned enrollment, is one of 9 that started in 2026, is one of 4 in phase 1/2, reaches primary completion later than 22 of the 33 other live ones, and was the 41st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About aflutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a single-arm, exploratory phase Ib/II study with a seamless design to evaluate the safety and efficacy of Vebreltinib combined with furmonertinib as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations (exon 19 deletion or L858R) and PD-L1 TPS ≥50%.

In the phase Ib part, 12-16 patients will be enrolled to compare the safety and early efficacy of Vebreltinib 100mg BID versus 150mg BID in combination with furmonertinib 80mg QD, and to determine the recommended phase II dose (RP2D).

In the phase II part, 37 patients (including evaluable patients from the RP2D cohort in phase Ib) will receive treatment at the RP2D. The primary endpoint is investigator-assessed median progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Exploratory endpoints will analyze the correlation between baseline MET abnormalities and treatment efficacy.

Read the detailed description

Patients with advanced NSCLC harboring EGFR mutations and high PD-L1 expression (TPS ≥50%) have primary resistance to third-generation EGFR-TKI monotherapy, with a median PFS of only 3.8-5.0 months, representing an unmet clinical need.

Basic research has shown that PD-L1 can inhibit protein tyrosine phosphatase through a non-immune pathway, leading to sustained MET phosphorylation and induction of MET amplification, which mediates EGFR-TKI resistance.

This study aims to overcome primary resistance by simultaneously blocking the EGFR and MET pathways through the combination of the MET inhibitor Vebreltinib and the third-generation EGFR-TKI furmonertinib.

The study is divided into two phases: the phase Ib dose-escalation phase adopts a parallel cohort design, enrolling two dose groups simultaneously. Each group initially enrolls 3 patients for a 28-day DLT observation period. If DLT ≤1 case, the cohort will be expanded to at least 6 evaluable patients; if DLT ≥2 cases, the cohort will be terminated. The RP2D will be determined comprehensively based on DLT incidence, incidence of grade ≥2 AEs, dose adjustment rate, and 8-week ORR.

The phase II efficacy-expansion phase will use the RP2D, with the primary endpoint being median PFS. It is expected that combination therapy will prolong the median PFS from 4 months in historical data to 8.5 months.

Patients will receive treatment until disease progression, death, withdrawal of informed consent, or intolerable toxicity. Imaging assessments will be performed every 8 weeks, with an additional tumor assessment on day 28 of cycle 1 for phase Ib patients. Safety assessments include adverse events, laboratory tests, electrocardiograms, and echocardiograms, graded according to NCI-CTCAE v5.0.

03

Conditions studied

  • Non-Small-Cell Lung Cancer

Keywords

  • EGFR mutation
  • PD-L1 high expression
  • Vebreltinib
  • Furmonertinib
  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily agree to participate in this study and sign a written form
  2. Age ≥18 years and ≤75 years, regardless of gender
  3. or cytologically confirmed locally advanced (stage IIIB-IIIC), , or recurrent (stage IV) non-small cell lung cancer, not amenable to surgical resection and definitive concurrent chemoradiotherapy
  4. No prior systemic antineoplastic therapy for advanced/metastatic disease Histologically or cytologically confirmed EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R point mutation)
  5. Central laboratory-confirmed Tumor Proportion Score (TPS) ≥50%
  6. At least one measurable target lesion according to v1.1 criteria
  7. Asymptomatic or locally treated stable are allowed.
  8. performance status 0-1
  9. Expected survival ≥3 months
  10. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. Histological type of small cell lung cancer or mixed small cell lung cancer
  2. Prior treatment with any EGFR-TKI or MET-TKI
  3. Presence of ALK fusion positive or ROS1 fusion positive
  4. Other active malignant tumors (except completely resected carcinoma in situ, basal cell or squamous cell skin cancer, or tumors with no recurrence for ≥3 years after curative treatment)
  5. Major surgery within 4 weeks before first dose (except resection, which requires ≥2 weeks); thoracoscopic or mediastinoscopy is excluded (requires ≥1 week)
  6. Require use of strong inhibitors or inducers within 1 week before first dose or during the study
  7. Uncontrolled systemic diseases
  8. Cardiac dysfunction: >470ms (average of three ECGs) at screening; functional class ≥3 or \<50%
  9. Dysphagia, active digestive system disease, or history of major gastrointestinal surgery that may affect drug absorption
  10. History of acute or chronic pancreatitis or pancreatic surgery
  11. Other conditions deemed unsuitable for participation by the investigator
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Vebreltinib plus Furmonertinib

    Participants with EGFR-sensitizing mutated, PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC) will receive Vebreltinib at the recommended phase 2 dose (RP2D) orally in combination with furmonertinib 80 mg orally once daily, until disease progression or unacceptable toxicity.

    Drug: Vebreltinib · Drug: Furmonertinib 80mg

Interventions

  • Administered orally on an empty stomach, 100mg or 150mg twice daily, with an interval of 12±4 hours between morning and evening doses. Dose adjustments are allowed based on toxicity, down to a minimum of 100mg BID

  • DrugAflutinibStudies of AflutinibAflutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered orally on an empty stomach, 80mg once daily, taken concurrently with Vebreltinib.

06

What researchers measure

Primary outcomes

  1. Phase Ib: Incidence of Dose-Limiting Toxicities as assessed by protocol-defined criteria and CTCAE v5.0

    Number of participants experiencing dose-limiting toxicities during the dose-escalation phase of the study, based on CTCAE v5.0 grading and protocol-specified DLT criteria

    Time frame: Up to 28 days from first dose

  2. Phase Ib: Incidence of Grade ≥2 Treatment-Emergent Adverse Events as assessed by CTCAE v5.0

    Number of participants experiencing Grade 2 or higher treatment-related adverse events

    Time frame: Up to 8 weeks from first dose

  3. Phase Ib: Rate of dose reduction, interruption, or discontinuation due to treatment-related adverse events as assessed by CTCAE v5.0

    Proportion of participants requiring dose reduction, interruption, or discontinuation due to treatment-related toxicity

    Time frame: Up to 8 weeks from first dose

  4. Phase II: Investigator-Assessed Progression-Free Survival (PFS)

    Time from first dose to first documented disease progression or death from any cause, assessed according to RECIST v1.1

    Time frame: From first dose until first documented disease progression or death from any cause, assessed up to 24 months

Secondary outcomes

  1. Phase Ib: Objective Response Rate (ORR)

    Proportion of participants achieving complete response (CR) or partial response (PR) per RECIST v1.1, assessed at 8 weeks after first dose

    Time frame: Up to 8 weeks from first dose

  2. Phase II: Objective Response Rate (ORR)

    Proportion of participants achieving complete response (CR) or partial response (PR) per RECIST v1.1

    Time frame: From first dose until first documented disease progression or death from any cause, assessed up to 24 months

  3. Phase II: Disease Control Rate (DCR)

    Proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) per RECIST v1.1

    Time frame: From first dose until first documented disease progression or death from any cause, assessed up to 24 months

  4. Phase II: Overall Survival (OS)

    Time from first dose to death from any cause

    Time frame: From first dose until death from any cause, assessed up to 36 months

Other outcomes

  1. Exploratory: Objective response rate by baseline MET aberration status as assessed by RECIST 1.1

    Proportion of participants achieving complete response (CR) or partial response (PR), stratified by presence or absence of baseline MET aberrations (MET amplification or MET overexpression)

    Time frame: From first dose until first documented disease progression or death from any cause, assessed up to 24 months

  2. Exploratory: Objective response rate by MET overexpression level as assessed by RECIST 1.1

    Proportion of participants achieving CR or PR, stratified by MET overexpression level ( IHC 1+,2+, 3+) measured by immunohistochemistry

    Time frame: From first dose until first documented disease progression or death from any cause, assessed up to 24 months

  3. Exploratory: Progression-free survival by baseline MET aberration status as assessed by RECIST 1.1

    Time from first dose to first documented disease progression or death from any cause, whichever occurs first, stratified by presence or absence of baseline MET aberrations (MET amplification or MET overexpression)

    Time frame: From first dose until first documented disease progression or death from any cause, assessed up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2027, 17 months later.

Of 124 non-industry phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 107. This study's planned 17 months is below that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 18, 2026
StartEst.
Jul 3, 2026
Primary completionEst.
Dec 3, 2027
CompletionEst.
Jun 3, 2029
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07655622
Lead sponsor
Second Affiliated Hospital of Nanchang University
Collaborators
Beijing Pearl Biotechnology Limited Liability Company
Responsible party
Jing Cai (Principal Investigator, Second Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Jun 18, 2026
Start date
Jul 3, 2026 (estimated)
Primary completion
Dec 3, 2027 (estimated)
Completion
Jun 3, 2029 (estimated)
Last update
Jun 18, 2026

Study contacts

Jing Cai, MD, PhD
Contact
cjdl879@163.com
+86+0791-86297662
Liangqian Lv, MD
Contact
369848857@qq.com
+86+0791-86297662
Anwen Liu, PhD
study chair · Second Affiliated Hospital of Nanchang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vebreltinib · Aflutinib

Start the discussion